secwatch.observer — SEC 8-K summary
======================================

Issuer:     Aurinia Pharmaceuticals Inc. (AUPH)
CIK:        0001600620
Form:       8-K
Filed at:   2026-08-19T20:11:54+00:00
Accession:  0001600620-26-000066
Event type: litigation
Sentiment:  positive
Materiality: 0.70
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Aurinia settles Teva patent litigation; generic voclosporin launch no earlier than Dec 7, 2036
--------------------------------------------------------------------------------

- Settlement with Teva resolves generic patent litigation over Teva's ANDA for 7.9 mg voclosporin oral capsules.
- Teva stipulates U.S. Patent Nos. 10,286,036 and 11,622,991 valid, enforceable, and infringed; patents expire December 2037.
- Teva may launch generic voclosporin no earlier than Dec 7, 2036, subject to FDA approval and certain defined contingencies.
- Aurinia's patent actions continue against DifGen, Dr. Reddy's, Galenicum, Hikma, Lotus, Sandoz, and Zydus in District of New Jersey.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1600620/000160062026000066/0001600620-26-000066-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1600620/000160062026000066/auph-20260819.htm
  HTML page:      https://secwatch.observer/filing/0001600620-26-000066

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer